Stifel Assumes FibroGen (FGEN) at Buy
Stifel analyst Annabel Samimy assumes coverage on FibroGen (NASDAQ: FGEN) with a Buy rating and a price target of $71.00.
Shares of FibroGen closed at $41.82 yesterday.
You May Also Be Interested In
- UPDATE: Stephens Starts First Solar (FSLR) at Overweight
- Credit Suisse Assumes Tradeweb Markets (TW) at Outperform
- Morgan Stanley Starts Raytron Technology Co Ltd (688002:CH) at Overweight
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!